September 24th 2021
Yelena Y. Janjigian, MD, further discusses the clinical significance of the FDA approval of nivolumab plus chemotherapy in the frontline treatment of patients with gastric cancer.
September 21st 2021
Michael Wang, MD, discusses the impact of acalabrutinib in patients with mantle cell lymphoma, the implications of the phase 2 ACE-LY-004 trial, and the challenges faced with treating those who harbor TP53 mutations.
September 14th 2021
Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.
September 7th 2021
David J. Pinato, MD, discusses combination strategies in HCC, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.
September 6th 2021
E. Gabriela Chiorean, MD, discusses some of the recent developments in pancreatic cancer, HCC, and NETs, as well as multidisciplinary approaches for treating these patients.
August 31st 2021
Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents
August 27th 2021
Sanaz Memarzadeh, MD, PhD, focuses on these ongoing multidisciplinary research directions aimed at improving outcomes for patients with ovarian cancer.
August 25th 2021
Paolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine in large B-cell lymphoma, results from the phase 2 LOTIS-2 trial, and future research directions with the agent.
August 18th 2021
Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.
August 18th 2021
Jonathan W. Goldman, MD, discusses the significance of the phase 3 CASPIAN and IMpower133 trials in small cell lung cancer and efforts made to optimize molecular testing.
August 16th 2021
Mark D. Pegram, MD, discusses the latest data in HER2-positive metastatic breast cancer.
August 10th 2021
A fixed duration of ibrutinib plus venetoclax has demonstrated durable efficacy when used in the frontline treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).
August 6th 2021
Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.
August 5th 2021
Though there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative therapeutic modality.
August 4th 2021
Chung-Han Lee, MD, PhD, discusses the goals of the phase 3 KEYNOTE-B61 study and the potential for immunotherapy/TKI combinations in non–clear cell RCC.
August 4th 2021
At a median follow-up of 42.8 months, frontline pembrolizumab plus axitinib continued to yield improved outcomes over sunitinib in patients with advanced clear cell renal cell carcinoma.
July 31st 2021
Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.
July 28th 2021
Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent.
July 27th 2021
Hossein Borghaei, DO, MS, discusses the clinical implications of the FDA approval of sotorasib in patients with KRAS G12C–mutant NSCLC.
July 23rd 2021
The CAR T-cell product tisagenlecleucel has been shown to elicit durable responses in adult patients with relapsed/refractory follicular lymphoma with a safety profile that compares favorably with other available products.